Pds Biotechnology CORP Form 4 insider transactions

PDS Biotechnology Corp's President and CEO, Frank Bedu-Addo, was granted 548,782 employee stock options with a $0.98 exercise price, vesting over four years.

PDS Biotechnology's Chief Scientific Officer, Gregory Conn, was granted 150,000 employee stock options with an exercise price of $0.98, vesting over four years.

PDS Biotechnology Corp's Chief Medical Officer, Kirk V. Shepard, was granted 300,000 employee stock options with a $0.98 exercise price and a 10-year term.

PDS Biotechnology Corp's Chief Financial Officer, Lars Boesgaard, was granted 300,000 employee stock options with an exercise price of $0.98, vesting over four years.

PDS Biotechnology Corp's Senior VP and General Counsel, Spencer D. Brown, was granted 300,000 employee stock options with a $0.98 exercise price.

PDS Biotechnology Corp's Chief Operating Officer, Stephan Toutain, was granted 300,000 employee stock options with an exercise price of $0.98.

PDS Biotechnology Corp Director Gregory Gene Freitag was granted 54,876 stock options with an exercise price of $0.98, vesting on January 12, 2027.

PDS Biotechnology Corp director Ilian Iliev was granted 54,876 employee stock options with an exercise price of $0.98, vesting on the first anniversary of the grant date.

PDS Biotechnology Corp director Kamil Ali-Jackson was granted 54,876 stock options with an exercise price of $0.98, vesting on January 12, 2027.

PDS Biotechnology Corp director Otis W. Brawley was granted 54,876 employee stock options with an exercise price of $0.98, vesting on the first anniversary of the grant date.

PDS Biotechnology Corp director Stephen C. Glover was granted 54,876 employee stock options with an exercise price of $0.98, vesting on the first anniversary of the grant date.

PDS Biotechnology Corp's President and CEO, Frank Bedu-Addo, was granted employee stock options totaling 450,000 shares, aligning executive incentives with long-term company performance.

PDS Biotechnology Corp's Chief Medical Officer, Kirk V. Shepard, was granted 150,000 employee stock options with an exercise price of $1.79, vesting over four years.

PDS Biotechnology Corporation has granted its Senior Vice President and General Counsel, Spencer D. Brown, a total of 206,000 employee stock options with varying exercise prices and vesting schedules.

PDS Biotechnology's Chief Financial Officer, Lars Boesgaard, was granted 150,000 employee stock options with a vesting schedule tied to continued service.

PDS Biotechnology's Chief Scientific Officer, Gregory Conn, was granted a total of 86,648 employee stock options with varying exercise prices and vesting schedules.

PDS Biotechnology Corporation's Chief Operations Officer, Stephan Toutain, was granted 150,000 employee stock options with a $1.79 exercise price, vesting over four years.

PDS Biotechnology Corp. Director Otis W. Brawley was granted 22,700 employee stock options with an exercise price of $1.75, vesting on the first anniversary of the grant date.

PDS Biotechnology Corp. director Kamil Ali-Jackson was granted 22,700 employee stock options with an exercise price of $1.75 per share, vesting fully on the first anniversary of the grant date.

PDS Biotechnology Corp's Director, Gregory Gene Freitag, was granted 22,700 employee stock options with an exercise price of $1.75, vesting on the first anniversary of the grant date.

PDS Biotechnology Corp (PDSB) announced that Director Ilian Iliev was granted 22,700 employee stock options with an exercise price of $1.75, vesting on the first anniversary of the grant date.

PDS Biotechnology Corp. Director Stephen C. Glover was granted 22,700 employee stock options with an exercise price of $1.75, vesting on the first anniversary of the grant date.

Gregory Gene Freitag, a director at PDS Biotechnology Corp, recently acquired shares and warrants of the company's common stock.

Director Stephen C. Glover of PDS Biotechnology Corp. reports purchasing shares and warrants of the company's common stock on February 28, 2025.

Gregory Gene Freitag, a director of PDS Biotechnology Corp, acquired 9,000 employee stock options on June 24, 2024.

Director Stephen C. Glover of PDS Biotechnology Corp. acquired 9,000 employee stock options on June 24, 2024, exercisable for common stock.

Director Richard Sykes of PDS Biotechnology Corp. reports the acquisition of 9,000 employee stock options on June 24, 2024.

Director Iliev Ilian of PDS Biotechnology Corp reports acquiring 9,000 stock options on June 24, 2024.

Director Otis W. Brawley acquired 9,000 employee stock options in PDS Biotechnology Corp on June 24, 2024.

Director Ali-Jackson Kamil of PDS Biotechnology Corp. acquired 9,000 employee stock options on June 24, 2024, exercisable after one year.